Earnings · US stocks

Ascendis Pharma A/S (ASND) earnings

Ascendis Pharma A/S published its quarterly report on 2026-11-12. The stock moved +4.80% in the 3 trading days after the report.

Report
quarterly report
Published
2026-11-12
Result
Great
Open earnings in Wave Radar

Stock move after the report

Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.

AfterReturnvs index
1 day+3.00%—
3 days+4.80%—

Report history

Over the last 8 reports, EPS beat the consensus estimate in 5 of them. The stock rose in the 3 trading days after 6 of 8 reports (average +4.55%).

PublishedEPSEPS surprise3 days after30 days after30d vs index
2026-11-121.71+48.70%+4.80%——
2026-08-130.90+17.39%-3.16%-9.69%-9.00%
2026-05-070.27+429.27%+1.17%-2.15%-3.91%
2026-02-11-0.55-124.49%+0.87%-0.40%+6.37%
2025-11-12-1.00-740.05%+8.70%+4.90%+3.89%
2025-08-07-0.64+49.30%+2.96%+3.85%-1.12%
2025-05-01-1.58-4.95%-2.76%+1.99%-4.91%
2025-02-12-0.64+45.35%+23.82%+25.21%+31.22%

The last 8 reported quarters. Moves count trading days from the first tradeable session after the report; "30d vs index" is the excess return over the market index.

Stock valuations: ASND

How to read this

Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.

Figures are generated automatically from Wave Radar's published market data and refresh after each market close.